Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Editorial

Guidance in an uncertain world

Iain K. Moppett1,*, Dale Gardiner2 and Daniel J. R. Harvey2

1Anaesthesia and Critical Care Research Group, Division of Clinical Neuroscience, Queen’s Medical Centre, University of Nottingham, Nottingham, UK and 2Critical Care Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK

*Corresponding author. E-mail: iain.moppett@nottingham.ac.uk

Keywords: clinical guidelines; coronavirus; COVID-19; evidence based medicine; guidelines; safety

In the face of the coronavirus pandemic, clinicians are looking to multiple sources for guidance. Clinical experience and professional training remain the bedrock for every healthcare practitioner, but guidance to support difficult decisions is needed. In an ideal world, there might be a series of definitive RCTs covering key areas such as who benefits from critical care admission and what are the risks of operating, or not operating? Even good-quality observational data would be helpful with all the caveats of confounding, association, and causation. To a large extent these are lacking for obvious reasons. So, healthcare workers and national organisations are trying to respond at great speed in a rapidly changing environment with the production and implementation of guidance. These are inevitably at best based on partial data, translation of theory and evidence from other situations, and collective wisdom.

Just as evidence-based medicine has a hierarchy of evidence, so we can consider a hierarchy of guidance: international guidance (WHO), national guidance from the ‘centre’ (government, courts, NHS England/Improvement in England in the UK,1 Centers for Disease Control and Prevention in the USA2), followed by national collegiate guidance (such as colleges and speciality associations3), local (NHS Trust or hospital grouping/hospital), departmental, and so on. Whether this translates into a hierarchy of acceptance of such guidance is unclear. There is some evidence that in normal times for doctors, sources of influence from colleagues from the medical profession are judged as more legitimate than professional or medical associations.4 We are not aware of empirical evidence of how healthcare professionals prioritise guidance in a crisis situation. There is inevitably a tension between a perceived need for military-style ‘command and control’ and the professional and individual autonomy to create and challenge centrally produced guidance.

Clinical guidelines normally take months or even years to produce,5,6 and are then subject to regular review and critique and updated as the evidence changes. Guidance is often required precisely because the evidence base is weak, or conflicted, and can therefore act as a catalyst for better quality data. Guidance in the coronavirus disease 2019 (COVID-19)
A fundamental question is which competing outcomes are we trying to balance? Rather than criticising any particular guidance, we would like to draw on recent experience of writing some national guidance,\(^7,8\) and the implementation and training of national guidance at a local level. We hope to draw out for readers, and perhaps for guideline groups, some of the issues that we now face. A fundamental question is which competing outcomes are we trying to balance?

There might be risks to the patient directly. Does coronavirus infection make outcomes worse after surgery, and importantly, how does that compare with not having that surgery? Is having a different operation, or none at all, likely to produce short- or long-term harm or benefit for the patient? The coronavirus pandemic is not a short-lived crisis. Choosing to limit investigation and treatment of curable life-limiting diseases, benign or malignant, is going to cause significant harm to those otherwise barely touched by coronavirus infection.

What about other patients? We are working in a severely resource-constrained environment. Most obvious is intensive care capacity including personnel, space, and equipment, but other resources are at a premium. Operating theatre time is limited owing to the triple hits of staff sickness, diversion of staff to other areas, and longer turnaround times for infection prevention and control. Impacts elsewhere in health and social care must not be forgotten. Avoiding surgery or changing operative approaches to mitigate impact on the operating room may have a fairly predictable effect of increasing workload on nursing and social care staff to the detriment of others.

And what about the staff themselves? All healthcare workers are exposing themselves to risk working with patients with known and unknown coronavirus status. At the benign end COVID-19 is an unpleasant illness, whereas at its worst it has caused the deaths of nurses and doctors. The knock-on effect of staff absence through self-isolation is significant, and in turn impacts on patients and colleagues.

Are there any solutions to these complex issues? We hesitantly suggest a few questions guideline writers might consider.

We have previously described an ethical decision making framework, MORAL Balance,\(^9,10\) to guide clinicians in making patient-centred shared decisions. An explicit ethical framework helps ensure decisions take account of the available facts and data, and recognise all of the relevant outcomes to the individuals and groups involved, before reaching a balanced decision. We suggest decision frameworks are applicable to organisational decisions as well (Table 1). Make sure of the facts. Has the group considered the robustness of the data they are using? Are they extrapolating from other scenarios in a reasonable way? If there is uncertainty, can it be quantified? There are some good data out there, and some research groups have made huge strides in trying to synthesise the research evidence in impressively short spaces of time.\(^11\) These groups are responsive and expert, so there seems little reason not to seek their advice.

Have other stakeholders been involved in the decisions? Some guideline development groups seem to have involved more than others. Making pronouncements that affect colleagues outside our own professional groups, without seeking their views, hardly engenders trust and risks making simple, avoidable mistakes.

It is vital that all outcomes of relevance for all those involved in the decision are taken into account and specified. For example, who is going to benefit from the decisions and recommendations in the guidance and how? Where is the harm, is it physical, psychological, financial, emotional? Are there other outcomes, perhaps difficult to articulate or admit that are influencing decision making, such as concerns about liability in a legal or a moral sense, or worries about media and public scrutiny? If so, are these influences justified and commensurate?

The use of a framework does not solve these problems or resolve all disagreements, and certainly does not prevent conflict between competing outcomes, for example staff vs patient safety. But it does facilitate a clear understanding of which factors are influencing decision making. Subsequent decisions are more transparent, better justified, and more robust.

Guidance without implementation is pointless. If there is conflict between existing documents, is the subsequent impact (need for rapid change, confusion, misunderstanding) justified? Is implementation credible in the real world: have the implications for personnel, training, time, and equipment been considered? Have clinicians with current, front-line experience been actively involved in development?

What is the mechanism to adapt and revise? No guidance is ever perfect, even before these times. Clearly, a balance needs...
to be struck between endless revisions leaving people confused, and a responsive, responsible attitude that realises when guidance just does not work or the data have improved. It is good science to change our view when new evidence comes to light.

High-level guidance is the science and the art of translating a complex, messy, constantly evolving picture into some semblance of order. We will get it wrong, but we must not stop trying.

**Author’s contributions**

Article design: IKM  
Writing and revision of all drafts of the article: IKM, DJRH  
Original concept of MORAL Balance: DJRH, DG  
Critical revision of the article: DG  
All authors fulfilled all the requirements of ICMJE and approved the final version of the manuscript to be published.

**Declarations of interest**

IKM is a board member of the British Journal of Anaesthesia. The other authors have no conflicts of interest to declare.

**References**

1. NHS England and NHS Improvement. Specialty guides for patient management 2020. Available from: https://www.england.nhs.uk/coronavirus/publication/specialty-guides/. [Accessed 15 April 2020]
2. Centers for disease control and prevention information for healthcare professionals 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html. [Accessed 15 April 2020]
3. ICM Anaesthesia COVID-19. Information, guidance and resources supporting the understanding and management of Coronavirus (COVID-19). Available from: https://icmanaesthesiacovid-19.org. [Accessed 15 April 2020]
4. Fernández LA, Martín JM, del Castillo JD, et al. Sources of influence on medical practice. J Epidemiol Community Health 2000; 54: 623–30
5. National Institute for Health and Care Excellence. How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS 2012. Available from: https://www.nice.org.uk/process/pmg6/resources/how-nice-clinical-guidelines-are-developed-an-overview-for-stakeholders-the-public-and-the-nhs-pdf-3304422725317. [Accessed 15 April 2020]
6. Practice advisory for the prevention, diagnosis, and management of infectious complications associated with neuraxial techniques: an updated report by the American society of anesthesiologists task force on infectious complications associated with neuraxial techniques and the American society of regional anesthesia and pain medicine. Anesthesiology 2017; 126: 585–601
7. NHS England. Clinical guide for the perioperative care of people with fragility fractures during the coronavirus pandemic 2020. Available from: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/C0066_Specialty-guide_-Fragility-Fractures-and-Coronavirus-v1-26-March.pdf. [Accessed 15 April 2020]
8. National Institute for Health and Care Excellence. COVID-19 rapid guideline: critical care in adults. Available from: https://www.nice.org.uk/guidance/NG159. [Accessed 15 April 2020]
9. Harvey DJR, Gardiner D. MORAL Balance decision-making in critical care. BJ A Educ 2019; 19: 68–73
10. Harvey DJR, Gardiner D. MORAL Balance 15 April 2020. Available from: www.moralbalance.org. [Accessed 15 April 2020]
11. Nuffield Department of Primary Care Health Sciences. Oxford COVID-19 Evidence Service 2020. Available from: https://www.phc.ox.ac.uk/covid-19/evidence-service. [Accessed 15 April 2020]